Inherited Retinal Dystrophies
VeonGen Therapeutics GmbH focuses on clinical research in inherited retinal disorders affecting vision loss linked to specific genetic variants, with particular attention to ABCA4 mutation-associated retinal dystrophy.
- Biallelic ABCA4 mutation-associated retinal dystrophy
- Genetic retinal degeneration
- Ocular disease progression
The sponsor’s research activity in this area centers on retinal imaging, visual function assessment, and clinical evaluation of disease-related changes in the eye.
Retinitis Pigmentosa
The sponsor also funds studies in retinitis pigmentosa caused by CNGA1 mutation, addressing a rare form of progressive retinal disease associated with impaired night vision and visual field loss.
- CNGA1-related retinitis pigmentosa
- Retinal photoreceptor degeneration
- Visual field impairment
Research in this domain includes attention to ocular structure, functional vision outcomes, and patient-specific measures of retinal disease burden.
Ophthalmic Safety and Tolerability
Clinical work supported by the sponsor includes evaluation of ocular safety and systemic tolerability in relation to treatment administration for retinal conditions.
- Ocular adverse events
- Systemic adverse events
- Laboratory abnormalities
Areas of interest include monitoring of treatment-related eye findings and overall clinical acceptability in patients with inherited retinal disease.
Vision Function and Imaging Endpoints
VeonGen Therapeutics GmbH supports studies that assess best corrected visual acuity, ocular imaging, and mobility function as indicators of clinical change in retinal disease.
- ETDRS visual acuity assessment
- Retinal imaging biomarkers
- Virtual reality mobility testing
These research interests reflect a focus on measuring both structural and functional aspects of vision impairment in rare inherited eye disorders.
